xaliproden hydrochloride
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Jul 1, 2002 (NCT00272051)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
HTR1A agonist
It has neurotrophic and neuroprotective activities. Although its mechanism of action is not fully understood, xaliproden appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death.
It binds competitively, and with high affinity (Ki = 2.0 nM) to 5-HT1a receptors
Chemistry & pharmacology
Loading structure…
SMILES
FC(F)(F)c1cccc(C2=CCN(CCc3ccc4ccccc4c3)CC2)c1- Mol. weight
- 381.44 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1512580 ↗
Also known as
- 1-(2-(naphth-2-yl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride
- 1-(2-(naphth-2-yl)ethyl)-4-(trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride
- sr-57746
- sr-57746
- sr57746a
- sr57746a
- sr57746a
- sr 57746a
- sr-57746a
- xaliproden
- xaliproden
- xaliproden
- xaliproden
- xaliproden
- xaliproden
- xaliproden hcl
- xaliproden hydrochloride
- xaliproden hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00603577 | Phase 3 | Jan 1, 2008 | Sanofi |
| NCT00305188 | Phase 3 | Dec 1, 2005 | Sanofi |
| NCT00103649 | Phase 3 | Nov 1, 2003 | Sanofi |
| NCT00104013 | Phase 3 | Nov 1, 2003 | Sanofi |
| NCT00272051 | Phase 3 | Jul 1, 2002 | Sanofi |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 5 | 5 | 1 | 2002 |
1 organizations
Page 1 / 1